Receptor News and Research

RSS

Exploring factors favoring transmission of SARS-CoV-2 Delta sublineage AY.4.2 over the Delta variant

In the present study, researchers isolated an infectious AY.4.2 strain of COVID-19 from the nasopharyngeal swab of a symptomatic individual from the Paris region. Then, they introduced the AY.4.2 signature mutations - T95I, Y145H, and A222V - in an expression plasmid coding the Delta protein to study the function of the AY.4.2 S protein.

13 Jan 2022

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

In a new study, researchers assessed the sera from COVID-19 infected and vaccinated individuals against the receptor-binding domain in the spike protein of the SARS-CoV-2 wildtype virus and its variants.

13 Jan 2022

The unique T cell response elicited by SARS-CoV-2 during a primary immune response by infection and vaccination

The distinctive characteristics of the T cell response generated by SARS-CoV-2 infection and vaccination and the relationship to CCCoVs and VOC was explored in a review published in Frontiers in Medicine.

13 Jan 2022

Moffitt experts provide insight on the role of B cell immunity in endometrial cancer

Endometrial cancer is the most common cancer of the female reproductive system. Patients who have active immune responses against cancer cells tend to have better outcomes, but much of what is known focuses on only one type of immune cell called T cells.

13 Jan 2022

Cannabinoids may prevent infection with SARS-CoV-2, including variants

A new study published in the Journal of Natural Products of the American Chemical Society and American Society of Pharmacognosy has shown that isolated cannabinoids or those in hemp extracts have the potential to prevent and treat the infection with the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – primarily by blocking viral cell entry.

13 Jan 2022

Study finds evidence for increased activity of the brain’s immune system long before dementia onset

Long before the onset of dementia, there is evidence for increased activity of the brain's immune system. Researchers from DZNE and the University Hospital Bonn come to this conclusion based on a study of more than 1,000 older adults.

12 Jan 2022

Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

Researchers examine the effects of disease-modifying therapies implemented for treating multiple sclerosis on the immune response to SARS-CoV-2 infection.

12 Jan 2022

Long-term use of blood pressure medication could be contributing to kidney damage

New kidney research from the University of Virginia School of Medicine is raising concerns that long-term use of drugs commonly prescribed to treat high-blood pressure and heart failure could be contributing to kidney damage.

12 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

Study finds a subset of vascular macrophages to be powerful ally in the fight against atherosclerosis

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behavior within the vessel wall.

11 Jan 2022

Engineering higher affinity SARS-CoV-2 antibodies

A new study describes the potential of engineered neutralizing antibodies that have a high affinity for the binding epitopes.

11 Jan 2022

Hemp compounds show ability to prevent the entry of SARS-CoV-2 into cells

Hemp compounds identified by Oregon State University research via a chemical screening technique invented at OSU show the ability to prevent the virus that causes COVID-19 from entering human cells.

11 Jan 2022

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy- also pioneered at Penn- for solid cancer tumors and offers a promising new strategy in the fight against cancer.

11 Jan 2022

Receptor News and Research

Exploring factors favoring transmission of SARS-CoV-2 Delta sublineage AY.4.2 over the Delta variant

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

The unique T cell response elicited by SARS-CoV-2 during a primary immune response by infection and vaccination

Moffitt experts provide insight on the role of B cell immunity in endometrial cancer

Cannabinoids may prevent infection with SARS-CoV-2, including variants

Study finds evidence for increased activity of the brain’s immune system long before dementia onset

Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

Long-term use of blood pressure medication could be contributing to kidney damage

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

Study finds a subset of vascular macrophages to be powerful ally in the fight against atherosclerosis

Engineering higher affinity SARS-CoV-2 antibodies

Hemp compounds show ability to prevent the entry of SARS-CoV-2 into cells

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Impact of post-exposure BNT162b2 prophylaxis against SARS-CoV-2 infections

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

Study finds T cell response mostly conserved against SARS-CoV-2 Omicron variant following infection or vaccination

Single-step RT-PCR for SARS-CoV-2 Omicron variant detection in respiratory samples

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

Providing recombinant antibody services and more within Europe

Latest tools for COVID-19 Omicron variant research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News